Pneumology
PRINCIPAL INVESTIGATORS
- Marta Andrea Diez Ferrer
- Eva Farrero Muñoz
- Carmen Monasterio Ponsa
- Mariana Mercedes Muñoz Esquerre
- Guillermo Rafael Suarez Cuartin
- Vanesa Vicens Zygmunt
CLINICAL RESEARCHERS
- Ana Córdoba Izquierdo
- Ester Cuevas Sales
- Roger Llatjos Sanuy
- Joaquim Llauradó Ovejas
- Rosa Maria Lopez Lisbona
- Sonia Lopez Monzoni
- Marta López Sánchez
- Patricio Luburich Hernaiz
- Susana Padrones Sanchez
- Rosa Planas Balague
- Enric Prats Soro
- Jesús Ribas Solà
- Neus Salord Oleo
POSTDOCTORAL RESEARCHERS
- Samantha Aso Gonzalez
- Meritxell Boada Perez
- Marta Gabasa Ferrandez
- Mercè Gasa Galmes
- Mònica Monteagudo Zaragoza
- Pere Trias Sabria
PREDOCTORAL RESEARCHERS
- Isabel Alfaya Fiaño
- Cristina Bellver Asperilla
- Guadalupe Bermudo Peloche
- Javier Burgos Lozano
- Hector Cabrerizo Carreño
- Paula Camps Massa
- Clara Canals Domenech
- Pau Cruzado Boix
- Eva Fontanilles Arbones
- Marta Hernandez Argudo
- Sandra Elisabet Orozco Echevarria
- Yolanda Ruíz Albert
- Mikel Sarasate Azkona
- Elsie Maria Vera Santiesteban
SCIENTIFIC SUPPORT
- Pablo Carrasco Cifuentes
- Joana Codina Jane
- Mireya Fuentes Prado
- Montserrat Navarro Rodriguez
- Marina Ruiz Moya
MANAGEMENT SUPPORT
- Maria Del Mar Chicote Guerra
Translational Medicine
Cardiovascular, Respiratory and Systemic Diseases and cellular aging
Scientific production
32
PAPERS
Average IF: 6,21
7
LED PAPERS
Average IF: 5,71
8 PUBLICATIONS IN FIRST DECILE
22 PUBLICATIONS IN FIRST QUARTILE
22 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Bermudo Peloche,G;Del Rio,B;Vicens Zygmunt,V;Bordas Martinez,J;Hernández,M;Valenzuela,C;Laporta,R et al, Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial., Eur. Resp. J., 2025;65(4):doi:10.1183/13993003.02249-2024
- Smit,JM;van der Zee,PA;Stoof,SCM;Van Genderen,ME;Snijders,D;Boersma,WG;Confalonieri,P et al, Predicting benefit from adjuvant therapy with corticosteroids in community-acquired pneumonia: a data-driven analysis of randomisedtrials, Lancet Resp. Med., 2025;13(3):221-233, doi:10.1016/S2213-2600(24)00405-3
- Lopez Lisbona,R;Calatayud,L;Gilabert Porres,J;Diez Ferrer,M;Borros,S;Ardanuy,C;Santos,S et al, Silver-coated silicone stents as an approach to prevent bacterial colonization of central airways after tracheobronchial stenting, Front Microbiol, 2025;161713806-1713806, doi:10.3389/fmicb.2025.1713806
- Alay,A;Marin,R;Aliagas,E;Gausachs,M;Ruiz Gil,M;Macia,I;Ojanguren,A et al, Single-cell RNA-sequencing as a potential approach for studying intratumor heterogeneity in pleural mesothelioma, Lung Cancer, 2025;207108679-108679, doi:10.1016/j.lungcan.2025.108679
- Bordas Martinez,J;Vercher Conejero,JL;Rodriguez Gonzalez,G;Notta,PC;Cabeza,CM;Cubero,N;Lopez Lisbona,RM et al, Mediastinal staging lymph node probability map in non-small cell lung cancer, Respir. Res., 2025;26(1):113-113, doi:10.1186/s12931-025-03121-z,
Research highlights
PROJECTS
6 Granted competitive projects
14 Ongoing competitive projects
15 Started clinical trials
47 Ongoing clinical trials
PUBLISHED WORKS
2 Clinical Guidelines
1 thesis
NETWORKS
CIBERES
EUILDReg
ERN-LUNG
Selected projects
- PMP22/00083. Integración de las características moleculares, genómicas, morfológicas, y ambientales para mejorar el diagnóstico y tratamiento de precisión en Enfermedades Pulmonares Intersticiales Difusas fibrosantes (Precision-EPID). Instituto de Salud Carlos III (ISCIII). 2023-2026. PI: MARIA MOLINA MOLINA.
- PI25/00507. Claves para la prevención secundaria en fibrosis pulmonar a través de medicina de precisión en fases tempranas. Instituto de Salud Carlos III (ISCIII). 2026-2028. PI: VANESA VICENS ZYGMUNT.
- S2/4.5/F0311. SHAPE-INTERREG_Sudoe2024_GASA,MERCÈ Programme d’Exercice pour Patients en Santé.. SOCIEDAD GESTORA INTERREG ESPACIO SUDOESTE EUROPEO SL INTERREG Sudoe. 2025-2028. PI: MERCÈ GASA GALMES.
- 203/U/2025. Early identification of treatment failure in pulmonary sarcoidosis through integrated multiomic analysis: The PREDICT-SARC study. Fundació La Marató de TV3. 2025- . PI: VANESA VICENS ZYGMUNT.
- PROJECTE INNOVA-ASMA. CONSORCI DE SALUT I D’ATENCIO SOCIAL DE CATALUNYA. Budget: 20.000€. 2025-2026. PI: MARIANA MERCEDES MUÑOZ ESQUERRE.